Impact of HI-NPPV Vs LI-NPPV on Tolerance Among AECOPD Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
DEVICE

High-intensity NPPV

In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.

DEVICE

Low-intensity NPPV

In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.

Trial Locations (1)

100020

Beijing Chao Yang Hospital, Beijing

All Listed Sponsors
lead

Beijing Chao Yang Hospital

OTHER

NCT06692023 - Impact of HI-NPPV Vs LI-NPPV on Tolerance Among AECOPD Patients | Biotech Hunter | Biotech Hunter